Clinical Outcomes of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron and Delta Variant: Systematic Review and Meta-analysis of 33 Studies Covering 6 037 144 Coronavirus Disease 2019-positive Patients

Overview

Journal Clin Microbiol Infect

Publisher Elsevier

Specialty Infectious Diseases

Date 2023 Mar 19

PMID 36934872

Authors

Fei-Hong Hu

Yi-Jie Jia

Dan-Yan Zhao

Xue-Lei Fu

Wan-Qing Zhang

Wen Tang

Shi-Qi Hu

Hua Wu

Meng-Wei Ge

Wei Du

Wang-Qin Shen

Bin Zhu

Hong-Lin Chen

Affiliations

Soon will be listed here.

Abstract

Background: Although the SARS-CoV-2 Omicron variant is considered to induce less severe disease, there have been no consistent results on the extent of the decrease in severity.

Objectives: To compare the clinical outcomes of COVID-19-positive patients with Omicron and Delta variant infection.

Data Sources: Searches were implemented up to 8 November 2022 in PubMed, Web of Science, BioRvix, and MedRvix.

Study Eligibility Criteria: Eligible studies were cohort studies reporting the clinical outcomes of COVID-19-positive patients with Omicron and Delta variant infection, including hospitalization, intensive care unit (ICU) admission, receiving invasive mechanical ventilation (IMV), and death.

Participants: COVID-19-positive patients with Omicron and Delta variant infection.

Assessment Of Risk Of Bias: Risk of bias was assessed employing the Newcastle-Ottawa Scale.

Methods Of Data Synthesis: Random-effect models were employed to pool the ORs and 95% CIs to compare the risk of clinical outcome. I was employed to evaluate the heterogeneity between studies.

Results: A total of 33 studies with 6 037 144 COVID-19-positive patients were included in this meta-analysis. In the general population of COVID-19-positive patients, compared with Delta, Omicron variant infection resulted in a decreased risk of hospitalization (10.24% vs. 4.14%, OR = 2.91, 95% CI = 2.35-3.60), ICU admission (3.67% vs. 0.48%, OR = 3.64, 95% CI = 2.63-5.04), receiving IMV (3.93% vs. 0.34%, OR = 3.11, 95% CI = 1.76-5.50), and death (2.40% vs. 0.46%, OR = 2.97, 95% CI = 2.17-4.08). In the hospitalized patients with COVID-19, compared with Delta, Omicron variant infection resulted in a decreased risk of ICU admission (20.70% vs. 12.90%, OR = 1.63, 95% CI = 1.32-2.02), receiving IMV (10.90% vs. 5.80%, OR = 1.65, 95% CI = 1.28-2.14), and death (10.72% vs. 7.10%, OR = 1.44, 95% CI = 1.22-1.71).

Conclusions: Compared with Delta, the severity of Omicron variant infection decreased.

Citing Articles

Epidemiology of the COVID-19 pneumonia in a group of hospitals from Madrid-Spain during the full period of the State of Alarm HM cohort.

Barberan J, Ramos M, Villanueva J, Villarez P, Villares P, Villareal M Rev Esp Quimioter. 2025; 38(2):97-107.

PMID: 39950446 PMC: 11894567. DOI: 10.37201/req/110.2024.

Population-Level SARS-CoV-2 RT-PCR Cycle Threshold Values and Their Relationships with COVID-19 Transmission and Outcome Metrics: A Time Series Analysis Across Pandemic Years.

De Arcos-Jimenez J, Quintero-Salgado E, Martinez-Ayala P, Rosales-Chavez G, Damian-Negrete R, Fernandez-Diaz O Viruses. 2025; 17(1).

PMID: 39861892 PMC: 11768943. DOI: 10.3390/v17010103.

Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study.

Boglione L, Crobu M, Pirisi M, Smirne C Viruses. 2025; 17(1).

PMID: 39861829 PMC: 11769566. DOI: 10.3390/v17010040.

Clinical characteristics and prognostic factors of COVID-19 in rheumatic patients and their family members: a retrospective study.

Fan Y, Wang Y, Du J, Wu R, Li J, Xiao C Front Immunol. 2025; 15:1439242.

PMID: 39742255 PMC: 11685756. DOI: 10.3389/fimmu.2024.1439242.

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).

Gentile I, Giaccone A, Scirocco M, Di Brizzi F, Cuccurullo F, Silvitelli M BMC Infect Dis. 2024; 24(1):1434.

PMID: 39696011 PMC: 11653931. DOI: 10.1186/s12879-024-10303-5.

References

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

Shoji K, Akiyama T, Tsuzuki S, Matsunaga N, Asai Y, Suzuki S . Clinical characteristics of COVID-19 in hospitalized children during the Omicron variant predominant period. J Infect Chemother. 2022; 28(11):1531-1535. PMC: 9364725. DOI: 10.1016/j.jiac.2022.08.004. View

Mayr F, Talisa V, Castro A, Shaikh O, Omer S, Butt A . COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. Nat Commun. 2022; 13(1):3647. PMC: 9233663. DOI: 10.1038/s41467-022-31402-4. View

Kawano Y, Patel N, Wang X, Cook C, Vanni K, Kowalski E . Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Ann Rheum Dis. 2022; 81(12):1742-1749. PMC: 9939910. DOI: 10.1136/ard-2022-222954. View

Graham M, Sudre C, May A, Antonelli M, Murray B, Varsavsky T . Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021; 6(5):e335-e345. PMC: 8041365. DOI: 10.1016/S2468-2667(21)00055-4. View

Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M . Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis. 2021; 116:38-42. PMC: 8713416. DOI: 10.1016/j.ijid.2021.12.357. View

Duong B, Larpruenrudee P, Fang T, Hossain S, Saha S, Gu Y . Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?. Int J Environ Res Public Health. 2022; 19(8). PMC: 9032753. DOI: 10.3390/ijerph19084586. View

Liu C, Ginn H, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A . Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; 184(16):4220-4236.e13. PMC: 8218332. DOI: 10.1016/j.cell.2021.06.020. View

Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J . Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022; 603(7902):700-705. PMC: 8942852. DOI: 10.1038/s41586-022-04462-1. View

10.

Stock S, Moore E, Calvert C, Carruthers J, Denny C, Donaghy J . Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study. Lancet Respir Med. 2022; 10(12):1129-1136. PMC: 9708088. DOI: 10.1016/S2213-2600(22)00360-5. View

11.

Christensen P, Olsen R, Long S, Snehal R, Davis J, Saavedra M . Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in.... Am J Pathol. 2022; 192(4):642-652. PMC: 8812084. DOI: 10.1016/j.ajpath.2022.01.007. View

12.

Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S . SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022; 603(7902):687-692. PMC: 8942849. DOI: 10.1038/s41586-022-04441-6. View

13.

Balint G, Voros-Horvath B, Szechenyi A . Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022; 7(1):151. PMC: 9077027. DOI: 10.1038/s41392-022-01009-8. View

14.

Ward I, Bermingham C, Ayoubkhani D, Gethings O, Pouwels K, Yates T . Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022; 378:e070695. PMC: 9344192. DOI: 10.1136/bmj-2022-070695. View

15.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

16.

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

17.

Veneti L, Boas H, Kristoffersen A, Stalcrantz J, Bragstad K, Hungnes O . Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022; 27(4). PMC: 8796289. DOI: 10.2807/1560-7917.ES.2022.27.4.2200077. View

18.

Jassat W, Abdool Karim S, Mudara C, Welch R, Ozougwu L, Groome M . Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health. 2022; 10(7):e961-e969. PMC: 9116895. DOI: 10.1016/S2214-109X(22)00114-0. View

19.

Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C . Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021; 40:101129. PMC: 8435265. DOI: 10.1016/j.eclinm.2021.101129. View

20.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View